Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02014909
Title A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Kolltan Pharmaceuticals, Inc.
Indications

melanoma

stomach cancer

lung non-small cell carcinoma

Her2-receptor positive breast cancer

head and neck cancer

colon cancer

Advanced Solid Tumor

Therapies

CDX-3379

CDX-3379 + Vemurafenib

CDX-3379 + Trastuzumab

CDX-3379 + Cetuximab

CDX-3379 + Erlotinib

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Sarah Cannon Research Institute Denver Colorado 80218 United States Details
Yale Cancer Center New Haven Connecticut 06511 United States Details
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201 United States Details
University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania 19104 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field